Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Single Arm Study to Investigate the Efficacy of Autologous EBV-specific T-cells for the Treatment of Patients With Aggressive EBV Positive Extranodal NK/T-cell Lymphoma (ENKTCL)

Next Previous
Trial Profile

A Phase 2 Single Arm Study to Investigate the Efficacy of Autologous EBV-specific T-cells for the Treatment of Patients With Aggressive EBV Positive Extranodal NK/T-cell Lymphoma (ENKTCL)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Baltaleucel-T (Primary) ; Asparaginase; Brentuximab vedotin; Dexamethasone; Gemcitabine; Oxaliplatin; Pralatrexate; Prednisone; Rituximab; Vinorelbine
  • Indications Extranodal NK-T-cell lymphoma
  • Focus Therapeutic Use
  • Acronyms CITADEL
  • Sponsors Kuur Therapeutics

    • Most Recent Events

    • 10 Mar 2020 According to an Kuur Therapeutics media release, Cell Medica has changed its name to Kuur Therapeutics.
    • 10 Jan 2019 Status changed from recruiting to discontinued.
    • 12 Dec 2017 Results (n=11, data cut off:31 Jul 2017) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top